Abzena appoints Stuart Bussell, PhD, as Head of Process Development in San Diego, CA

18th May 2020

Cambridge, UK and San Diego, CA,  18 May 2020 – Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to GMP services for large molecules and bioconjugates, announced it has appointed Dr. Stuart Bussell as Head of Process Development in San Diego.

Stuart has been in the industry for more than 25 years with increasing levels of responsibilities.  For the past three years he has been the Vice President, Development at InhibRx.  He has broad experience in cell culture, protein purification, analytical testing, formulation development, and process scale up and GMP manufacturing.   At InhibRx, he focused on the development of platform processes to deliver rapid results and high yields (>3g/L) with >50% purification recoveries and stable formulations of >3 years.

Prior to his role at InhibRx, Stuart was the Senior Director of Process Development at Sutro Biopharma, Inc. for four years.   He also worked for Ambrx, Inc., EGen Corporation, GenWay Biotech Inc., Prizm Pharmaceuticals, and General Electric Silicone Products in a variety of roles, and he was a Postdoctoral Associate at UCLA Department of Chemical Engineering in Los Angeles, California.

Stuart received his PhD in Chemical Engineering with a minor in Biochemistry at Cornell University in Ithaca, New York, and his BS (Summa Cum Laude) in Chemical Engineering with minor in Management from Rensselaer Polytechnic Institute in Troy, New York.

For more information, please contact:


About Abzena

Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and bioconjugation drug development and manufacturing in the biopharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is owned by Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.